Cite
HARVARD Citation
Iskierka-Jażdżewska, E. et al. (2020). Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia & lymphoma. 61 (3), pp. 699-706. [Online].